Clinical trials: enrolling by invitation
Craniofacial Defects
Long-term Safety and Performance of CMF Porous Titanium Implants
The goal of this retrospective study is to evaluate the clinical characteristics, efficiency, safety, and long-term performance of craniomaxillofacial (CMF) Porous Titanium Implants within the standard of care across children (0…
- Trial name
- CMF SafeTi Fit (NCT06910033)
- Testing
- Craniomaxillofacial (CMF) porous titanium implant
- Where
- 2 sites in Denmark, France
- Volunteers
- 200 people
- Sponsor
- Materialise
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
- Trial name
- FOREST-HCM (NCT04848506)
- Testing
- Aficamten (5 - 20 mg)
- Where
- 141 sites in United States, Argentina and 17 more
- Volunteers
- 900 people
- Sponsor
- Cytokinetics
Open-Angle Glaucoma
A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma
The goal of this study is to learn about outcomes after bio-reinforced canaloplasty surgery in patients with OAG. The key question the study aims to answer is: How much does the surgical procedure lower pressure inside the eye…
- Trial name
- BOOST (NCT07520175)
- Testing
- AlloSpan Canal Platform Bio-Reinforced Canaloplasty
- Where
- 9 sites in United States
- Volunteers
- 300 people
- Sponsor
- Iantrek, Inc.
Temporomandibular Joint Disorders
Long-term Safety and Performance of Materialise's Patient-specific TMJ System.
This is a long-term (10 years), retrospective-prospective, observational, single-arm, monocenter study of patients to be treated with the Materialise TMJ Total Arthroplasty System for TMJ replacement.
- Trial name
- NCT06951178
- Testing
- TMJ Total Arthroplasty System (TMJ System)
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Materialise
Erectile Dysfunction
IT Matters: The Erectile Restoration Registry
The objective of the It MATTERS registry is to collect Real-World Data (RWD) to monitor the safe and effective use of commercially available Boston Scientific Corporation (BSC) penile prostheses
- Trial name
- NCT04200937
- Testing
- Tactra Malleable, Spectra™ Concealable Penile Prothesis, AMS Ambicor™ Inflatable Penile Prosthesis
- Where
- 25 sites in United States, China and 1 more
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Boston Scientific Corporation
Advanced/Metastatic Malignant Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 in patients with advanced/metastatic solid tumors.
- Trial name
- NCT06115642
- Testing
- HLX43, HLX10
- Where
- 14 sites in United States, China and 1 more
- Volunteers
- 367 people
- Sponsor
- Shanghai Henlius Biotech
Erythropoietic Protoporphyria
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.
- Trial name
- NCT05883748
- Testing
- DISC-1459
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 230 people
- Sponsor
- Disc Medicine, Inc
Multiple System Atrophy
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the…
- Trial name
- NCT07729852
- Testing
- ATH434
- Where
- 4 sites in France
- Volunteers
- 7 people
- Sponsor
- Alterity Therapeutics
Antibody-mediated Rejection, Microvascular Inflammation
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and then developed antibody-mediated rejection (AMR) or microvascular inflammation (MVI).
- Trial name
- NCT07444489
- Testing
- Felzartamab
- Where
- 14 sites in United States
- Volunteers
- 201 people
- Sponsor
- Biogen
Growth Hormone Deficiency in Children, Born Small for Gestational Age
Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
Participants are free to decide if they want to take part in this study or not. The study will be conducted to collect information about the influence of adherence to growth hormone therapy with Norditropin® in children and…
- Trial name
- NCT03972345
- Testing
- Norditropin® FlexPro®
- Where
- Germany
- Volunteers
- 750 people
- Sponsor
- Novo Nordisk A/S
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS
The goal of this real world data study is to evaluate the clinical utility of remote patient monitoring solution (using Byteflies' EpiCare@Home with reduced EEG montage and other vital signs) with Dravet and LGS patients (ages 3…
- Trial name
- TETRIS (NCT07225231)
- Testing
- Byteflies Remote patient monitoring solution (with reduced EEG)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Byteflies
Haemophilia B
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
The purpose of this study is to collect data on adverse events from third party registries that include information about adverse events from patients with haemophilia B treated with nonacog beta pegol.
- Trial name
- NCT03690336
- Testing
- Nonacog beta pegol
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Focal Epilepsy, Tonic-Clonic Seizures
An Open-label Study of XEN1101 in Epilepsy
This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of…
- Trial name
- X-TOLE4 (NCT05718817)
- Testing
- XEN1101
- Where
- 152 sites in United States, Argentina and 23 more
- Volunteers
- 880 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Haemophilia A
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from…
- Trial name
- NCT04682145
- Testing
- Turoctocog alfa pegol
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Novo Nordisk A/S
Noonan Syndrome
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
This is a non-interventional registry of children treated with Norditropin® for short stature due to Noonan Syndrome (NS). This study aims to provide data on long-term growth evolution and safety of Norditropin® as well as Health…
- Trial name
- NCT05308927
- Testing
- Norditropin
- Where
- 3 sites in France
- Volunteers
- 221 people
- Sponsor
- Novo Nordisk A/S
Chronic Spontaneous Urticaria
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3…
- Trial name
- NCT07256392
- Testing
- barzolvolimab, Standard of Care
- Where
- 182 sites in United States, Argentina and 28 more
- Volunteers
- 1,370 people
- Sponsor
- Celldex Therapeutics
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
This is an open-label, monotherapy, extension study to evaluate the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
- Trial name
- NCT07161700
- Testing
- SPT-300
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Rhematoid Arthritis, Osteo Arthritis of the Knee
Persona SoluTion PPS Femur PMCF
The goal of this study is to generate clinical evidence and evaluate the safety and performance of the Persona® SoluTion® PPS Femurs in the US market, with data supporting global regulatory submissions, including CE marking under…
- Conditions
- Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis), Polyarthritis
- Trial name
- NCT07286513
- Testing
- Total knee arthroplasty
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Zimmer Biomet
Kidney Diseases, Kidney Injury
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and/or biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney…
- Conditions
- Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
- Trial name
- ID-ENTITY (NCT07393594)
- Testing
- Blood tests, TRAC( cell free DNA) and T-ID
- Where
- 14 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Transplant Genomics, Inc.
Haemophilia A
Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation…
- Trial name
- NCT07653139
- Testing
- No treatment given
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S